Published online September 1, 2004
PEDIATRICS Vol. 114 No. 3 September 2004, pp. 895-896 (doi:10.1542/10.1542/peds.2004-1140)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henderson, T. A.
Right arrow Articles by Hartman, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henderson, T. A.
Right arrow Articles by Hartman, K.
Related Collections
Right arrow Neurology & Psychiatry
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Aggression, Mania, and Hypomania Induction Associated With Atomoxetine

Theodore A. Henderson, MD, PhD
Private Practice,
Child and Adolescent Psychiatry,
Denver, CO 80122
Matrix ADHD Diagnostic Clinic,
Denver, CO 80122
Neurobehavioral Research,
Brain Matters, Inc,
Denver, CO 80122

Keith Hartman, MD
Private Practice,
Osceola, WI 54020

The first 20% of the full text of this article appears below.

To the Editor.—

Atomoxetine is a selective inhibitor of norepinephrine reuptake recently approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). In 4 double-blind, placebo-controlled clinical trials leading to Food and Drug Administration approval, ~70% of child and adolescent subjects responded based on reductions in scores on a variety of measures for ADHD symptomatology.1,2 Although no major risks were identified in these trials, a small percentage of subjects seem to have experienced mood destabilization. Irritability was reported in 8% of subjects, and mood swings were observed in 2% of subjects. Four subjects discontinued the drug because of irritability or aggression.3 Our clinical experience has been that mood destabilization is a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
A. D. Mosholder, K. Gelperin, T. A. Hammad, K. Phelan, and R. Johann-Liang
Hallucinations and Other Psychotic Symptoms Associated With the Use of Attention-Deficit/Hyperactivity Disorder Drugs in Children
Pediatrics, February 1, 2009; 123(2): 611 - 616.
[Abstract] [Full Text] [PDF]